James Ford - GlaxoSmithKline PLC President
| GSK Stock | USD 37.32 0.36 0.96% |
President
Mr. James Ford serves as Senior Vice President General Counsel of the Company. James joined the CET in 2018, when he was appointed Senior Vice President and General Counsel. He joined GSK in 1995 and has served as General Counsel Consumer Healthcare, General Counsel Global Pharmaceuticals, Vice President of Corporationrationrate Legal and Acting Head of Governance, Ethics and Compliance. Prior to GSK, James was a solicitor at Clifford Chance and DLA. He holds a law degree from University of East Anglia and a Diploma in Competition Law from Kings College. He is qualified as a solicitor in England and Wales, and is an attorney at the New York State Bar. since 2018.
| Tenure | 7 years |
| Address | 79 New Oxford Street, London, United Kingdom, WC1A 1DG |
| Phone | 44 20 8047 5000 |
| Web | https://www.gsk.com |
GlaxoSmithKline PLC Management Efficiency
The company has Return on Asset of 0.0658 % which means that on every $100 spent on assets, it made $0.0658 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2833 %, implying that it generated $0.2833 on every 100 dollars invested. GlaxoSmithKline PLC's management efficiency ratios could be used to measure how well GlaxoSmithKline PLC manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to 0.07. The value of Return On Capital Employed is expected to slide to 0.10. Change To Liabilities is expected to rise to about 596.5 M this year, although the value of Total Current Liabilities will most likely fall to about 11.5 B.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Leon Wang | AstraZeneca PLC ADR | N/A | |
| Alisha Alaimo | Biogen Inc | N/A | |
| Jyoti Mehra | Gilead Sciences | 48 | |
| Murdo Gordon | Amgen Inc | 58 | |
| Roger Perlmutter | Merck Company | 67 | |
| John Elicker | Bristol Myers Squibb | 59 | |
| Peter Fasolo | Johnson Johnson | 61 | |
| Esteban Santos | Amgen Inc | 57 | |
| Nicholas Donoghoe | AbbVie Inc | 37 | |
| Rupert Vessey | Bristol Myers Squibb | 56 | |
| Jonathan Graham | Amgen Inc | 63 | |
| Robin Kramer | Biogen Inc | 59 | |
| Patrick MD | Novartis AG ADR | 55 | |
| Michael Severino | AbbVie Inc | 55 | |
| Iskra Reic | AstraZeneca PLC ADR | N/A | |
| Anabella Villalobos | Biogen Inc | 65 | |
| Julie Gerberding | Merck Company | 64 | |
| Katarina Ageborg | AstraZeneca PLC ADR | N/A | |
| Pam Cheng | AstraZeneca PLC ADR | 55 | |
| Steven Mizell | Merck Company | 60 | |
| James Bradner | Novartis AG ADR | 49 | |
Management Performance
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.0658 |
GlaxoSmithKline PLC ADR Leadership Team
Elected by the shareholders, the GlaxoSmithKline PLC's board of directors comprises two types of representatives: GlaxoSmithKline PLC inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GlaxoSmithKline. The board's role is to monitor GlaxoSmithKline PLC's management team and ensure that shareholders' interests are well served. GlaxoSmithKline PLC's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GlaxoSmithKline PLC's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lynn Elsenhans, Independent Non-Executive Director | ||
| Luke Miels, President - Global Pharmaceuticals | ||
| Hal Barron, Chief Scientific Officer, President - Research & Development, Executive Director | ||
| Harry Dietz, Non-Executive Independent Director, Scientific and Medical Expert | ||
| Emma Walmsley, Chief Executive Officer, Executive Director | ||
| CA BSc, President Development | ||
| Philip Thomson, President Affairs | ||
| Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare | ||
| Charles Bancroft, Non-Executive Independent Director | ||
| Constantin Fest, Senior Relations | ||
| Vivienne Cox, Independent Non-Executive Director and Workforce Engagement Director | ||
| Nick Stone, SVP Relations | ||
| Diana Conrad, Senior Vice President - Human Resources | ||
| Roger Connor, President - Global Manufacturing & Supply | ||
| Phil Thomson, Senior Vice President - Global Communications | ||
| Judy Lewent, Non-Executive Independent Director | ||
| Shobie Ramakrishnan, Chief Digital and Technology Officer | ||
| Sarah EltonFarr, Head Relations | ||
| Julie Brown, Chief Officer | ||
| Urs Rohner, Non-Executive Independent Director | ||
| Marvinder Banga, Senior Non-Executive Independent Director | ||
| Anne Beal, Non-Executive Independent Director | ||
| Jesse Goodman, Non-Executive Independent Director and Scientific and Medical Expert | ||
| Laurie Glimcher, Non-Executive Independent Director and Scientific & Medical Expert | ||
| Julie ACA, CFO Director | ||
| Nick Hirons, Senior Vice President - Global Ethics and Compliance | ||
| Sally Jackson, Senior Vice President - Global Communications and CEO Office | ||
| James Ford, Senior Vice President, Group General Counsel, Legal and Compliance | ||
| Victoria Whyte, Company Secretary | ||
| Tony Wood, Chief Scientific Officer - Designate | ||
| David Redfern, Chief Strategy Officer | ||
| Regis Simard, President - Pharmaceutical Supply Chain | ||
| Jonathan Symonds, Independent Non-Executive Chairman of the Board | ||
| Iain Mackay, Chief Financial Officer, Executive Director | ||
| Karenann Terrell, Chief Digital and Technology Officer | ||
| Deborah Waterhouse, Chief Executive Officer - ViiV Healthcare | ||
| MPH MD, Scientific Expert |
GlaxoSmithKline Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GlaxoSmithKline PLC a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.28 | ||||
| Return On Asset | 0.0658 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.31 % | ||||
| Current Valuation | 93.07 B | ||||
| Shares Outstanding | 2.02 B | ||||
| Shares Owned By Insiders | 0.06 % | ||||
| Shares Owned By Institutions | 18.29 % | ||||
| Number Of Shares Shorted | 13.51 M | ||||
| Price To Earning | 11.80 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.232 | Dividend Share 0.63 | Earnings Share 2.2 | Revenue Per Share | Quarterly Revenue Growth 0.013 |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.